Between 1 March and 19 August 2019, 706 participants were randomised in total , in a 6:1 ratio: approximately 506 to once-weekly subcutaneous cagrilintide at 0.3, 0.6, 1.2, 2.4 or 4.5 mg (100102 per dose group), 99 to once-daily liraglutide 3.0 mg, and 101 to volume-matched placebo
Lateral allosterism in the glucagon receptor family: glucagon-like peptide 1 induces G-protein-coupled receptor heteromer formation
2 A closer look at our services If you need a primary care provider, MinuteClinic may be an option for you
Your GLP-1 Journey Deserves Real Support No matter where you are with semaglutide or tirzepatide, a dedicated care team can transform your entire experience
Regulatory frameworks are still developing, but there is a growing interest from governments to promote health supplements, which could catalyze market growth in the coming years